The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Recombinant human ACE2: acing out angiotensin II in ARDS therapy
Open accessAbstract
Acute respiratory distress syndrome (ARDS) is a devastating inflammatory lung disorder that is frequently associated with multiple organ dysfunction leading to high mortality. The mechanisms underlying ARDS are multifactorial, and are thought to include the reninangiotensin system (RAS) [1, 2]. The RAS is a coordinated complex hormonal cascade that is composed of angiotensinogen, angiotensinconverting enzyme (ACE) and its homolog angiotensin converting enzyme 2 (ACE2), and angiotensin II (Ang II) type 1 and type 2 receptors (AT1, AT2). ACE cleaves the decapeptide Ang I into the octapeptide Ang II, while ACE2 cleaves a single residue from Ang II to generate Ang 1-7, which in turn blocks Ang II and inhibits ACE [3]. Thus, the ACE2 axis negatively regulates the ACE axis. Great attention has been focused on the role of the RAS in blood pressure homeostasis and cardiovascular function, but there is also increasing interest in understanding the pathophysiological role of the RAS in lung. While only 20% of capillary endothelial cells in all other organs, including the heart, express ACE, it is detectable in the entire capillary network of the alveoli in human lung [4]. Therefore, conversion of Ang I to Ang II can readily occur in the lung by abundant ACE in pulmonary vessels. This may contribute to rapid responses of vasoconstriction in the pulmonary circulation and low blood flow, leading to ventilation/perfusion mismatch in conditions such as tissue hypoxia. On the other hand, ACE2 is primarily produced in Clara cells and type II alveolar epithelial cells [5] and epithelial injury is a critical event in the development of ARDS in humans; thus, the ability to produce ACE2 is severely impaired, resulting in dominant ACE activities during ARDS and/or ventilatorinduced lung injury (VILI) [1, 6]. Increasing evidence has emerged that reactive oxygen species (ROS), especially nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and hydrogen peroxide (H2O2), act as upstream regulators of RAS and ACE activity in various cells and tissues [7]. The RAS in turn induces production of ROS that function as intracellular and intercellular second messengers to modulate many downstream signaling cascades. In normal conditions, the interplay between the ROS and RAS is important in maintaining pulmonary function and integrity. Under ARDS and VILI conditions, this vicious cycle feedback loop contributes to lung injury and remodeling through oxidative damage [6, 8]. Midkine (MK), a heparin-binding growth factor, has been recently demonstrated as a novel modulator of RAS in the context of ARDS and VILI [6]. The plasma concentration of MK increased dramatically in patients with ARDS [6], and an up-regulation of MK in lung epithelial cells is reported in response to cyclic mechanical stress [6]. Exposure to MK protein results in an enhanced ACE expression in primary human lung cells [9]. MK has been shown to stimulate the RAS by acting as an upstream signaling molecule of Ang II and mediates lung–kidney crosstalk leading to development of RASassociated fibrosis [9]. The RAS—specifically Ang II via AT1 and AT2 receptors—has a number of effects: (1) induction of pulmonary vasoconstriction and vascular permeability in response to hypoxia resulting in pulmonary edema; (2) stimulation of the lung production of inflammatory cytokines directly and indirectly by targeting bradykinin; (3) acceleration of the Fas-induced apoptosis in alveolar * Correspondence: zhangh@smh.ca Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Room 619, LKSKI, 30 Bond Street, Toronto, ON M5B 1W8, Canada Interdepartmental Division of Critical Care Medicine, Departments of Anesthesia and Physiology, University of Toronto, Toronto, ON, Canada
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Cited by
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684
Self-citationThe hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Abou-Ismail, M. Y., Diamond, A., Kapoor, S., Arafah, Y., & Nayak, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.029 · Cited by 694
The pathophysiology of ‘happy’ hypoxemia in COVID-19
Dhont, S., Derom, E., Van Braeckel, E., Depuydt, P., & Lambrecht, B. N. (2020) · Respiratory Research · doi:10.1186/s12931-020-01462-5 · Cited by 544
Clinical Characteristics of Covid-19 in China
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2005203 · Cited by 475
Guo, J., Huang, Z., Lin, L., & Lv, J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016219 · Cited by 464
Metadata
- Authors
- Zhang, H., & Baker, A.
- Venue
- Critical Care
- Published
- 2017-12
- Volume
- 21
- Issue
- 1
- Pages
- 305-305
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2773619306
- Cited by
- 183
- References
- 2
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant human ACE2: acing out angiotensin II in ARDS therapy. https://app.cochat.ai/papers/10.1186/s13054-017-1882-z
- The paper
- Zhang, H., & Baker, A. (2017). Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Critical Care. https://doi.org/10.1186/s13054-017-1882-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.